GW Henssler & Associates Ltd. boosted its holdings in Cerner Co. (NASDAQ:CERN) by 0.2% in the first quarter, Holdings Channel reports. The institutional investor owned 197,301 shares of the company’s stock after acquiring an additional 369 shares during the quarter. GW Henssler & Associates Ltd.’s holdings in Cerner were worth $14,182,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in CERN. CX Institutional grew its position in Cerner by 79.1% in the fourth quarter. CX Institutional now owns 394 shares of the company’s stock worth $31,000 after acquiring an additional 174 shares in the last quarter. Ancora Advisors LLC raised its stake in shares of Cerner by 1.6% during the fourth quarter. Ancora Advisors LLC now owns 11,406 shares of the company’s stock valued at $895,000 after acquiring an additional 181 shares during the last quarter. 9258 Wealth Management LLC raised its stake in Cerner by 3.3% in the fourth quarter. 9258 Wealth Management LLC now owns 6,288 shares of the company’s stock worth $493,000 after buying an additional 199 shares in the last quarter. Beacon Financial Group raised its stake in Cerner by 0.8% in the fourth quarter. Beacon Financial Group now owns 24,820 shares of the company’s stock worth $2,007,000 after buying an additional 207 shares in the last quarter. Finally, Ironwood Investment Counsel LLC grew its holdings in Cerner by 3.3% in the fourth quarter. Ironwood Investment Counsel LLC now owns 6,704 shares of the company’s stock worth $526,000 after purchasing an additional 215 shares during the period. Institutional investors and hedge funds own 83.01% of the company’s stock.

In related news, CFO Mark J. Erceg acquired 10,761 shares of the firm’s stock in a transaction that occurred on Wednesday, March 3rd. The stock was bought at an average price of $69.66 per share, for a total transaction of $749,611.26. Also, CFO Mark J. Erceg acquired 10,547 shares of the firm’s stock in a transaction that occurred on Wednesday, March 10th. The shares were bought at an average price of $71.13 per share, with a total value of $750,208.11. Over the last ninety days, insiders have purchased 31,963 shares of company stock valued at $2,250,251. 0.33% of the stock is owned by corporate insiders.

Shares of NASDAQ:CERN traded down $0.89 on Tuesday, reaching $75.10. The company’s stock had a trading volume of 35,776 shares, compared to its average volume of 2,358,690. Cerner Co. has a 52-week low of $63.11 and a 52-week high of $84.20. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.28 and a current ratio of 2.29. The company has a 50-day simple moving average of $73.47 and a 200 day simple moving average of $74.84. The company has a market cap of $22.70 billion, a P/E ratio of 29.68, a PEG ratio of 2.35 and a beta of 0.76.

Cerner (NASDAQ:CERN) last released its quarterly earnings results on Tuesday, February 9th. The company reported $0.78 EPS for the quarter, hitting analysts’ consensus estimates of $0.78. Cerner had a net margin of 14.28% and a return on equity of 18.14%. The firm had revenue of $1.40 billion during the quarter, compared to analysts’ expectations of $1.39 billion. During the same period in the previous year, the company earned $0.75 EPS. The firm’s revenue for the quarter was down 3.3% compared to the same quarter last year. On average, equities research analysts forecast that Cerner Co. will post 2.47 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 20th. Investors of record on Tuesday, April 6th were paid a dividend of $0.22 per share. The ex-dividend date was Monday, April 5th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.17%. Cerner’s dividend payout ratio is presently 36.51%.

Several research analysts have weighed in on CERN shares. Morgan Stanley increased their price target on shares of Cerner from $64.00 to $70.00 and gave the stock an “underweight” rating in a research report on Thursday, February 11th. Truist raised their price objective on shares of Cerner from $72.00 to $82.00 in a research report on Thursday, February 11th. Piper Sandler raised their price objective on shares of Cerner from $84.00 to $85.00 and gave the company an “overweight” rating in a research report on Tuesday, February 16th. UBS Group downgraded shares of Cerner from a “buy” rating to a “neutral” rating and set a $82.00 price objective on the stock. in a research report on Thursday, February 11th. Finally, KeyCorp raised their price objective on shares of Cerner from $82.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 11th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. Cerner presently has a consensus rating of “Buy” and a consensus price target of $81.50.

Cerner Company Profile

Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. The company offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers.

Featured Article: What is required to own or exchange cryptocurrency?

Want to see what other hedge funds are holding CERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerner Co. (NASDAQ:CERN).

Institutional Ownership by Quarter for Cerner (NASDAQ:CERN)

Receive News & Ratings for Cerner Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerner and related companies with MarketBeat.com's FREE daily email newsletter.